Adverse Events from Ingestion of OTC Eye Drops and Nasal Sprays

By Tasnima Nabi, PharmD Candidate c/o 2016

The FDA has issued warnings on accidental ingestion of over-the-counter eye drops and nasal sprays because they can cause serious harm in children at and under the age of five. Ingestion of as little as 0.6 ml of OTC nasal decongestants and redness-relief eye drops has been reported to require hospitalization.1

The FDA collected data reported to their Adverse Event Reporting System databases and to the National Electronic Injury Surveillance System – Cooperative Adverse Drug Event Surveillance (NEISS-CADES) database between 1985 and 2012 on accidental ingestion of products containing tetrahydrozoline, oxymetazoline, or naphazoline.1 Tetrahydrozoline, oxymetazoline, and naphazoline are imidazolines used to narrow blood vessels in irritated eyes and congested noses. When used in topical and nasal administration, there is little absorption of imidazolines into the general circulation. Oral ingestion, however, leads to systemic effects.2Of the 96 cases, 53 required hospitalization due to nausea, vomiting, lethargy, tachycardia, decreased respiration, bradycardia, hypotension, hypertension, sedation, somnolence, mydriasis, stupor, hypothermia, drooling, and coma.1

A common misconception is that OTC eye drops and nasal sprays are safe and harmless because they do not need prescriptions and even though they are used in very sensitive areas. However, it is important to stress that medicines are safe and harmless when used as directed.

As a general precaution, medicine should be kept out of reach of children. A large part of this problem, however, lies in how OTC eye drops and nasal sprays are bottled; neither is contained in child-resistant packaging. Although a proposal was made by the U. S. Consumer Product Safety Commission in January 2012 to require CR packaging of products containing at least 0.08 mg of imidazole derivatives, the rule still has not been finalized.1,2 There is no doubt that a push for child-resistant packaging on these medicines will greatly reduce the harm due to accidental ingestion.

SOURCES:

  1. FDA Drug Safety Communication: Serious adverse events from accidental ingestion by children of over-the-counter eye drops and nasal sprays. U. S. Food and Drug Administration Web site. http://www.fda.gov/Drugs/DrugSafety/ucm325257.htm#list. Accessed on November 21, 2012.
  2. Ballot Vote Sheet. United States Consumer product Safety Comission Web site. http://www.cpsc.gov/library/foia/foia12/brief/imidazolines.pdf. Accessed on November 21, 2012.

 

eMAR

Recent Posts

Oxidative Stress and Its Impact on Vitiligo

By: Zurriya Faran, PharmD Candidate c/o 2031 The visible loss of skin pigmentation often indicates…

2 months ago

Thiamine Metabolic Dysfunction Syndrome: Overview, importance, MOA, and treatment

By: Archana Murugan, PharmD candidate c/o 2029 Overview             Thiamine metabolic dysfunction syndrome (TMDS) refers…

2 months ago

Updated Guidelines for the Treatment of Multidrug and Rifampin-Resistant TB and Promising New Anti-TB Drugs in Phase 2/3 Trials

By: Kevin Lee, PharmD Candidate c/o 2028, Angela Yin, PharmD Candidate c/o 2028             The…

2 months ago

Sixth Year Perspective: Interview with Ariella Zadrima, PharmD Candidate, c/o 2026

By: Aymon Choudhury, PharmD Candidate c/o 2027 APPE questions: How did your APPE rotations shape…

2 months ago

Foundayo: The New Drug in the GLP-1 market

By: Sariah Grant, PharmD Candidate c/o 2027             The rise of glucagon-like peptide -1 receptor…

2 months ago

Should All Drugs be OTC? Risks and Consequences of the FDA Commissioner Statement

By: Amanda Kastel, PharmD Candidate c/o 2027 In February 2026, FDA Commissioner Marty Makary stated…

2 months ago